Skip to the main content.

Amyotrophic Lateral Sclerosis

Phase 3

Case Studies

Here you can edit the background of the section

Key Takeaways

This six-month phase 3 study was seeking to enroll 108 patients with amyotrophic lateral sclerosis (ALS) who had a mutation in the superoxide dismutase type 1 (SOD1) gene. BBK had successfully supported phase 1 enrollment.

Since patients may not have known whether they had the mutation, genetic testing was included as part of the initial screening.

Because of the limited patient population, efforts were needed to ensure that all study participants remained engaged with services that facilitated their participation.

The investigational drug QALSODY (tofersen) has since been approved by the FDA – its approval has been considered a major scientific advancement as the first treatment to target a genetic cause of ALS.

amyotrophic lateral sclerosis
ALS-Poster-Mockup-2

Challenges

Only about two percent of all ALS patients have a mutation in the SOD1 gene.

Because many ALS patients do not know if they have a mutation in the SOD1 gene, they may not immediately identify with the study opportunity.

Patient burden when traveling to and from study appointments.

Concern among patients about the possibility of being randomized to the placebo group.

 

 

 

Solutions

BBK developed materials to keep the study top of mind at study sites and to support patient identification and consent.

Patient and referring-physician materials were educational and approachable. They helped staff to quickly identify potentially eligible patients while also providing patients and caregivers with the information necessary to facilitate consent.

Patient engagement services included reimbursement and in-country / cross-border travel for patients and their caregivers.

BBK created a unique brand that could resonate across multiple studies within the sponsor’s ALS pipeline.

 

 

Digital recruitment materials

Impact

Through a detailed prescreening process designed to rank and identify potential participants based on their knowledge of their condition, including ALS diagnosis history, SOD1 testing status, history of familial ALS, and willingness to participate in clinical research, BBK generated over 1,700 highly qualified referrals.

  • Increase-Referrals_ICON-1 1,700 Referrals generated by BBK.

  • Sites_ICON 77% Percentage of sites that adopted BBK’s TCN™ Card reimbursement program.

  • Countries-ICON-1 68% Percentage of sites that adopted BBK’s TCN™ Arrive travel program.

Travel and Reimbursement

BBK ‘s TCN™ Card reimbursement program ensured patients would be reimbursed immediately anywhere in the world. BBK’s TCN™ Arrive travel program extended to in-country and cross-border travel for patients and their caregivers.

Concierge Services

Ambulance Transports

Site: Île-de-France, France
A patient in France required an ambulance to transport them to and from study visits as their condition progressed.

  • BBK’s concierge specialists sourced a local ambulance.

  • BBK coordinated payments directly to the local vendor as the site was unable to afford the expense.

Wheelchair Accessibility

Site: Quebec, Canada
A patient in Quebec required added support as their mobility declined.

  • BBK’s concierge specialists identified a partner in Quebec who could provide a wheelchair-accessible vehicle.

  • BBK coordinated accessible hotel rooms for the patient.

Hospital Bed Rental

Hospital-BedSite: Florida, United States
Staff at a site in Florida requested assistance from BBK’s concierge specialists to help source a hospital bed that could be rented for one of their patients.

  • BBK’s concierge specialists coordinated a rental bed with a trapeze bar that could be used in a hotel room. 

Study Program-Level Support

BBK supported the sponsor’s pipeline of related ALS studies with branding and material development. The study logos differentiated each study while maintaining a strong brand consistency across all materials.

ALS-StudyProgram-Brands
Physician Materials

Download the PDF version of this case study today:

Subscribe to stay connected

Share this page:

Familial Amyloid Polyneuropathy — Neurology and Gene Therapy — Phase 3

case-studies-icon Case Studies

October 12, 2021

Pediatric Spinal Muscular Atrophy — Neurology and Rare Disease — Phase 2

case-studies-icon Case Studies

December 13, 2021

Major Depressive Disorder — Mental Health — Pivotal Phase 3 Study

case-studies-icon Case Studies

February 5, 2022

BBK Worldwide, LLC
117 Kendrick St., Suite 600
Needham, MA 02494 United States

        Terms & Conditions  Privacy Policy

        © 2024 BBK Worldwide. BBK Worldwide is a Publicis Health company.

        Facebook LinkedIn YouTube
        Facebook LinkedIn YouTube

        Terms & Conditions  Privacy Policy

        © 2024 BBK Worldwide. BBK Worldwide is a Publicis Health company.